Efficacy of buparlisib in treating breast cancer. (12th December 2017)

• Record Type: Journal Article
• Authors: Robert, Marie; Frenel, Jean-Sébastien; Bourbouloux, Emmanuelle; Berton Rigaud, Dominique; Patsouris, Anne; Augereau, Paule; Gourmelon, Carole; Campone, Mario
• Is Part Of: Expert opinion on pharmacotherapy. Volume 18:Number 18(2017)
• Page Start: 2007
• Page End: 2016
• Publication Date: 2017-12-12
• Subjects: Breast cancer -- buparlisib -- chemotherapy -- endocrine therapy -- phosphatidylinositol-3-kinase; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2017.1410139
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Breast cancer is the most frequent cancer in women. Despite a decline in breast cancer mortality, prognosis of advanced breast cancer remains poor. In a desperate need to improve breast cancer outcomes, newer agents that target molecular pathways are being tested. Deregulation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) is frequently found in breast cancer. This can lead to resistance of endocrine therapy and anti-HER2 therapies. Targeting this pathway may restore sensitivity to these compounds. Buparlisib (BKM-120) is an orally active pan-PI3K inhibitor evaluated in different tumor types. Areas covered : Buparlisib is one of the most investigated PI3K inhibitors. Preclinical and clinical studies of buparlisib in breast cancer are analyzed and discussed. This article reviews the status of buparlisib, completed and ongoing trials, and its safety. Expert opinion : PI3K inhibitors show promising results in breast cancer. However, we raise a number of issues including the identification of biomarkers to predict treatment response and strategies to counteract resistance. Moreover, its toxicity profile could limit its extensive use.